Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity

Hypertension is a recognized comorbidity for COVID-19. The association of antihypertensive medications with outcomes in patients with hypertension is not fully described. However, angiotensin-converting enzyme 2 (ACE2), responsible for host entry of the novel coronavirus (SARS-CoV-2) leading to COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaberi-Douraki, Majid, Meyer, Emma, Riviere, Jim, Gedara, Nuwan Indika Millagaha, Kawakami, Jessica, Wyckoff, Gerald J., Xu, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233397/
https://www.ncbi.nlm.nih.gov/pubmed/34172790
http://dx.doi.org/10.1038/s41598-021-92734-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233397/
https://www.ncbi.nlm.nih.gov/pubmed/34172790
http://dx.doi.org/10.1038/s41598-021-92734-7

Ejemplares similares